- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Hemab, Seaport Therapeutics surge as clinical-stage biotechs make trading debuts | 1 | Seeking Alpha | ||
| SEAPORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | 'M&A used to be the only way to go': Why Seaport Therapeutics' CEO opted for route to upsized $255M IPO | 1 | FierceBiotech | ||
| Fr | Neuropsychiatric therapeutics Seaport Therapeutics prices upsized IPO at $18, the high end of the range | 1 | Renaissance Capital | ||
| Fr | Seaport Therapeutics Set For Nasdaq Debut After Raising $255 Million In IPO | 1 | Benzinga.com | ||
| Fr | PureTech Health notes pricing of Seaport Therapeutics for Nasdaq IPO | 7 | Alliance News | ||
| Fr | Investors back Seaport Therapeutics IPO in tentative return for biotech listings | 3 | The Armchair Trader | ||
| Fr | Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each | 531 | AFX News | WASHINGTON (dpa-AFX) - Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range. The company... ► Artikel lesen | |
| Fr | PureTech Health PLC - PureTech's Seaport Therapeutics Prices Upsized IPO Nasdaq: SPTX | 4 | RNS | ||
| Fr | Seaport Therapeutics legt Preis für Börsengang auf 18 US-Dollar fest | 1 | Investing.com Deutsch | ||
| Fr | Seaport Therapeutics prices IPO at $18 per share | 2 | Investing.com | ||
| Di | Seaport Therapeutics and Hemab target $180m IPOs as biotech listings accumulate | 1 | Pharmaceutical Technology | ||
| Mo | Seaport Therapeutics, Hemab chart courses for $180M IPOs to fund depression, clotting candidates | 1 | FierceBiotech | ||
| Mo | Neuropsychiatric therapeutics Seaport Therapeutics sets terms for $201 million IPO, pricing this week | 1 | Renaissance Capital | ||
| Mo | Drug developer Seaport Therapeutics seeks up to $212M in US IPO | 2 | Seeking Alpha | ||
| Mo | Drug developer Seaport Therapeutics targets $912 million valuation in US IPO | 1 | Reuters | ||
| Mo | Seaport Therapeutics, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 10.04. | Seaport Therapeutics, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 02.04. | Seaport Therapeutics reports positive Phase 1 data for GlyphAgo | 2 | Investing.com | ||
| 25.03. | Seaport Therapeutics veröffentlicht positive klinische Daten zu Depressionsmittel GlyphAllo | 2 | Investing.com Deutsch | ||
| 25.03. | Seaport Therapeutics publishes GlyphAllo clinical data | 1 | Investing.com |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ETON PHARMACEUTICALS | 28,910 | +19,86 % | Eton Pharmaceuticals relaunches HEMANGEOL (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution | HEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiationEton has integrated full Eton Cares patient support, including $0 co-pay for eligible... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 86,91 | -1,18 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| LB PHARMACEUTICALS | 31,355 | -1,12 % | This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday | ||
| BIOHAVEN | 9,630 | +0,57 % | Biohaven Ltd.: Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results | Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM)... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,390 | -1,83 % | KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer | ||
| AQUESTIVE THERAPEUTICS | 4,190 | +2,07 % | Vergessene Biotech-Chance: Kann Aquestive Therapeutics vor dem Durchbruch stehen? | Aquestive Therapeutics steht trotz operativer Fortschritte und potenziell wertvoller Pipeline unter massivem Bewertungsdruck. Die Aktie notiert deutlich unter früheren Kursniveaus, während sich fundamentale... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,340 | +4,46 % | Weekly Buzz: Sanofi, Regeneron Pharmaceuticals Get FDA Nod; It's A No For AbbVie, Grace Therapeutics; Eli Lilly Acquires Kelonia | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning... ► Artikel lesen | |
| SHUTTLE PHARMACEUTICALS | 0,708 | -31,93 % | Shuttle Pharmaceuticals Holdings Inc.: United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation | Gaithersburg, Maryland--(Newsfile Corp. - May 1, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle") has entered into a definitive merger agreement to acquire United Dogecoin... ► Artikel lesen | |
| OMNIAB | 1,400 | +0,72 % | OmniAb (OABI) Well-Positioned for Momentum Build-Up in 2026 | ||
| MILESTONE PHARMACEUTICALS | 1,870 | +3,89 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST (etripamil) Nasal Spray for the Treatment of PSVT | FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic... ► Artikel lesen | |
| JOURNEY MEDICAL | 5,185 | +0,68 % | Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights | Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately... ► Artikel lesen | |
| DARE BIOSCIENCE | 2,350 | +3,07 % | Daré Bioscience, Inc.: Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update | Company Highlights Commercial Launch of DARE to PLAY Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 13,110 | +3,80 % | Generate Biomedicines Prices IPO At $16/shr | WASHINGTON (dpa-AFX) - Generate Biomedicines, Inc. (GENB) on Thursday priced its initial public offering of 25,000,000 shares of stock at $16 per share, raising gross proceeds of $400 million.The... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS | 1,905 | +0,79 % | Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity | WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| ATRIUM THERAPEUTICS | 13,400 | +4,93 % | Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration | SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics... ► Artikel lesen |
SEAPORT THERAPEUTICS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 19,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SEAPORT THERAPEUTICS INC finden Sie auf Wallstreet Online.